fbxl7 Antibody

What is FBXL7 and why is it important in biomedical research?

FBXL7 is a member of the F-box protein family that functions as a component of SCF (SKP1-CUL1-F-box) ubiquitin ligase complexes. These complexes play critical roles in protein ubiquitination and subsequent proteasomal degradation. Research has shown that FBXL7 exhibits tissue-specific and cancer-specific expression patterns with divergent roles in different tumor types. In glioma tissues, FBXL7 expression is significantly upregulated compared to normal adjacent tissues, with expression levels progressively increasing with higher glioma grades (I through IV) . Conversely, in pancreatic cancer, FBXL7 appears to be downregulated in tumor tissues compared to adjacent normal tissues, suggesting a potential tumor suppressor role . This dual nature makes FBXL7 an intriguing target for cancer biology investigations and highlights the importance of reliable antibodies for its detection and characterization.

What applications are FBXL7 antibodies most commonly used for?

FBXL7 antibodies are particularly valuable for several research applications including immunohistochemistry (IHC), western blotting, immunoprecipitation (IP), and co-immunoprecipitation (co-IP). For IHC, these antibodies have been successfully used to detect FBXL7 expression in patient tissue samples, allowing researchers to correlate expression levels with clinical parameters such as tumor grade and patient survival . In western blot applications, FBXL7 antibodies enable quantitative assessment of protein levels in cell lines and tissue samples. One study demonstrated the utility of FBXL7 antibodies in co-IP assays to investigate the interaction between FBXL7 and Snail1, a key transcription factor in the epithelial-mesenchymal transition (EMT) process . This versatility makes FBXL7 antibodies essential tools for investigating both expression patterns and functional interactions.

How can I validate the specificity of an FBXL7 antibody?

Validating antibody specificity is critical for ensuring reliable experimental results. For FBXL7 antibodies, a multi-pronged validation approach is recommended:

• Knockdown/knockout controls: Compare antibody signal between wild-type cells and cells with FBXL7 knockdown (using shRNA) or knockout. Studies have demonstrated this approach using shFBXL7 lentivirus-infected cells alongside control cells .

• Overexpression controls: Examine antibody signal in cells overexpressing FBXL7. The signal should increase proportionally to the level of overexpression.

• Western blot band size verification: Confirm that the observed band matches the predicted molecular weight of FBXL7.

• Multiple antibodies targeting different epitopes: When possible, use different antibodies that recognize distinct regions of FBXL7 to confirm expression patterns.

• Tissue expression comparison: Compare antibody staining across tissues known to have differential FBXL7 expression, such as normal brain tissue versus glioma tissue, or normal pancreatic tissue versus pancreatic cancer tissue .

Which cell lines are most suitable for FBXL7 antibody validation?

Based on the available research, several cell lines have been documented to express detectable levels of FBXL7 and would be appropriate for antibody validation:

When validating an FBXL7 antibody, it is advisable to include both cell lines with high expression (such as U87 or BxPC-3) and those with lower expression (such as NHAs or PANC1) to confirm the dynamic range of detection. Additionally, including cells with experimentally modulated FBXL7 levels (knockdown or overexpression) provides robust controls for specificity assessment.

How can I reconcile the contradictory expression patterns of FBXL7 observed in different cancer types?

The contradictory expression patterns of FBXL7 in different cancers represent an intriguing research puzzle. In glioma, FBXL7 shows significantly increased expression compared to normal tissue and correlates with poor prognosis, suggesting an oncogenic role . In contrast, pancreatic cancer tissues exhibit decreased FBXL7 expression compared to adjacent normal tissues, indicating a potential tumor suppressor function .

To investigate these discrepancies, consider the following approaches:

• Comprehensive tissue analysis: Use FBXL7 antibodies to systematically analyze expression across multiple cancer types and matched normal tissues. Create a tissue microarray when possible.

• Functional studies: Perform knockdown and overexpression studies in different cell types to determine cell-specific consequences of FBXL7 modulation.

• Analysis of downstream targets: Investigate whether FBXL7 targets different substrate proteins in different cell types. For example, in pancreatic cancer cells, FBXL7 induces ubiquitination and degradation of Snail1 . Identify whether different substrates are targeted in glioma cells.

• Signaling pathway analysis: Examine how FBXL7 interacts with tissue-specific signaling networks. In Drosophila, Fbxl7 interacts with the protocadherin Fat in pathways regulating tissue growth . Cell-type specific interaction partners may explain different functional outcomes.

• Mutation or post-translational modification analysis: Sequence FBXL7 from different cancer types to identify potential mutations or analyze post-translational modifications that might alter function.

This contradictory behavior likely reflects the complex context-dependent roles of ubiquitin ligase components and highlights the need for careful tissue-specific analysis when studying FBXL7.

What are the optimal protocols for using FBXL7 antibodies in co-immunoprecipitation studies?

Co-immunoprecipitation (co-IP) is a valuable technique for investigating FBXL7's protein-protein interactions, such as its relationship with Snail1. Based on successful co-IP experiments in the literature , the following protocol is recommended:

• Cell lysis: Harvest cells and lyse in a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, and protease inhibitor cocktail. For studying ubiquitination, include 10 mM N-ethylmaleimide to inhibit deubiquitinating enzymes.

• Pre-clearing: Pre-clear lysate with protein A/G beads for 1 hour at 4°C.

• Immunoprecipitation: Incubate pre-cleared lysate with anti-FBXL7 antibody (2-5 μg) overnight at 4°C with gentle rotation. For reverse co-IP, use antibodies against the suspected interaction partner (e.g., anti-Snail1).

• Bead binding: Add protein A/G beads and incubate for 2-4 hours at 4°C.

• Washing: Wash beads 4-5 times with lysis buffer containing reduced detergent (0.1% NP-40).

• Elution: Elute proteins by boiling in SDS sample buffer.

• Analysis: Analyze by western blotting, probing for both FBXL7 and potential interaction partners.

Critical controls include:

• IgG-only immunoprecipitation

• Input lysate (whole cell extract) samples

• Reverse co-IP with antibodies against the interaction partner

• Validation in FBXL7-knockdown cells

This approach has successfully demonstrated the physical interaction between FBXL7 and Snail1 in pancreatic cancer cells .

How can FBXL7 antibodies be used to investigate ubiquitination activity?

FBXL7, as an F-box protein, functions within SCF ubiquitin ligase complexes to target proteins for ubiquitination and subsequent degradation. To investigate this activity:

• Ubiquitination assay:

  • Treat cells with proteasome inhibitors (e.g., MG132, 10 μM for 6-8 hours)

  • Perform immunoprecipitation with antibodies against the suspected substrate (e.g., Snail1)

  • Analyze by western blotting with anti-ubiquitin antibodies to detect ubiquitination levels

• Protein stability assays:

  • Perform cycloheximide chase assays with and without FBXL7 overexpression/knockdown

  • Collect samples at different time points (0, 1, 2, 4 hours) and analyze by western blotting

  • Quantify protein levels to determine degradation rates

• Co-IP for SCF complex components:

  • Use FBXL7 antibodies to immunoprecipitate the protein

  • Probe for other SCF components (SKP1, CUL1) to confirm complex formation

• Substrate identification:

  • Perform immunoprecipitation with FBXL7 antibodies followed by mass spectrometry

  • Compare results between control and FBXL7-overexpressing cells to identify enriched proteins

This approach has been successfully applied to demonstrate that FBXL7 induces Snail1 ubiquitination and proteasomal degradation in pancreatic cancer cells. As shown in the literature, FBXL7 overexpression increased Snail1 ubiquitination, and treatment with MG132 prevented FBXL7-mediated Snail1 degradation .

What methodological considerations are important when using FBXL7 antibodies for EMT analysis?

Epithelial-mesenchymal transition (EMT) is a critical process in cancer progression, and FBXL7 has been shown to regulate EMT in pancreatic cancer cells. When using FBXL7 antibodies to study this process:

• Multi-marker analysis: Always examine multiple EMT markers alongside FBXL7:

  • Epithelial markers: E-cadherin

  • Mesenchymal markers: N-cadherin, Vimentin

  • EMT transcription factors: Snail1, Snail2, ZEB1, Twist

• Co-localization studies: Use dual immunofluorescence with FBXL7 antibodies and EMT markers to assess spatial relationships.

• Time-course experiments: EMT is a dynamic process, so analyze FBXL7 and EMT marker expression at multiple time points after EMT induction.

• Functional validation: Complement expression studies with functional assays:

  • Migration assays (e.g., Transwell)

  • Invasion assays

  • 3D culture morphology

• Controls and validation:

  • Use positive controls known to undergo EMT

  • Include FBXL7 knockdown and overexpression samples

  • Validate key findings with multiple antibody clones

Research has demonstrated that FBXL7 knockdown in BxPC-3 pancreatic cancer cells decreased E-cadherin expression while increasing Vimentin and N-cadherin levels. Conversely, FBXL7 overexpression in PANC1 cells had the opposite effect, suggesting that FBXL7 negatively regulates EMT in pancreatic cancer . This relationship appears to be mediated through FBXL7's ability to induce Snail1 degradation, highlighting the mechanistic link between ubiquitination and EMT regulation.

What controls should be included when using FBXL7 antibodies to study cancer progression?

When designing experiments to investigate FBXL7's role in cancer progression using antibodies, the following controls are essential:

• Expression controls:

  • Positive tissue controls: Samples known to express FBXL7 (e.g., normal brain tissue for glioma studies, normal pancreatic tissue for pancreatic cancer studies)

  • Negative controls: Tissues with minimal FBXL7 expression or FBXL7 knockout samples

  • Gradient controls: When possible, include samples representing different disease stages to capture expression changes during progression

• Antibody controls:

  • Isotype controls: Matched isotype antibodies to control for non-specific binding

  • Peptide competition: Pre-incubation of antibody with immunizing peptide to confirm specificity

  • Secondary-only controls: Omit primary antibody to assess secondary antibody background

• Genetic modulation controls:

  • FBXL7 knockdown cells: Generate using validated shRNAs (as demonstrated in both glioma and pancreatic cancer studies)

  • FBXL7 overexpression cells: Particularly important for loss-of-function studies

  • Rescue experiments: Re-express FBXL7 in knockdown cells to confirm specificity of observed phenotypes

• Functional controls:

  • Known FBXL7 substrates: Monitor Snail1 levels as a functional readout of FBXL7 activity

  • Proliferation markers: Include Ki-67 staining to assess proliferation changes

  • EMT markers: E-cadherin, N-cadherin, and Vimentin to assess EMT status

Including these controls will help ensure the reliability and interpretability of results when studying FBXL7's role in cancer progression.

How can I optimize FBXL7 antibodies for detecting low-abundance expression in clinical samples?

Detecting low-abundance FBXL7 in clinical samples can be challenging. Based on successful approaches in the literature:

• Signal amplification methods:

  • Use tyramide signal amplification (TSA) for immunohistochemistry

  • Consider polymer-based detection systems over traditional ABC methods

  • Implement extended antibody incubation times (overnight at 4°C)

• Sample preparation optimization:

  • Test multiple antigen retrieval methods (citrate, EDTA, and enzymatic)

  • Optimize fixation protocols for fresh samples

  • Consider using thicker sections (5-7 μm) for IHC to increase signal

• Antibody selection and dilution:

  • Test multiple antibody clones targeting different FBXL7 epitopes

  • Perform careful dilution series to determine optimal concentration

  • Consider directly conjugated primary antibodies to reduce background

• Protocol modifications for low expression:

  • Reduce washing stringency (shorter wash times, gentler buffers)

  • Block with both protein blockers and Fc receptor blockers

  • Use cooled CCD cameras for imaging fluorescent signals

• Validation in model systems:

  • Confirm antibody sensitivity in cell lines with known low FBXL7 expression

  • Use recombinant FBXL7 protein dilution series to establish detection limits

These approaches have enabled researchers to detect differential FBXL7 expression in clinical samples, including the observation that 87.5% of adjacent normal pancreatic tissues showed strongly positive FBXL7 expression, while only 44.0% of pancreatic cancer tissues showed positive signal .

What approaches can be used to study FBXL7 antibody-detected expression in relation to patient outcomes?

Correlating FBXL7 expression with clinical outcomes is a critical aspect of cancer research. Based on published methodologies:

• Patient stratification:

  • Categorize patients into high and low FBXL7 expression groups using mean expression as a cut-off point

  • Use appropriate statistical methods to determine optimal cut-off values (ROC curve analysis)

  • Consider continuous expression values in addition to dichotomized groups

• Survival analysis:

  • Perform Kaplan-Meier survival analysis comparing high vs. low FBXL7 expression groups

  • Calculate hazard ratios using Cox proportional hazards regression

  • Adjust for clinicopathological variables in multivariate analysis

• Correlation with clinical parameters:

  • Analyze FBXL7 expression in relation to tumor grade, stage, and other clinical features

  • Create contingency tables and use appropriate statistical tests (chi-square, Fisher's exact)

  • Generate forest plots to visualize associations across multiple parameters

• Tissue microarrays (TMAs):

  • Develop TMAs containing samples from patients with known outcomes

  • Include multiple cores per patient to account for tumor heterogeneity

  • Ensure adequate representation across disease stages

This approach has been applied successfully in glioma research, where patients with higher FBXL7 expression showed significantly poorer survival compared to those with lower expression (P < 0.001). This relationship was particularly pronounced in Grade IV glioma samples .

How can I address inconsistent results when using FBXL7 antibodies across different experimental systems?

Inconsistent results when using FBXL7 antibodies may reflect both technical issues and genuine biological differences. To address these challenges:

• Antibody-related factors:

  • Lot-to-lot variation: Use the same antibody lot for comparative studies or validate each new lot

  • Storage conditions: Follow manufacturer recommendations precisely

  • Recognition epitopes: Different antibodies may recognize different FBXL7 isoforms or post-translationally modified forms

• Cell/tissue-specific considerations:

  • Expression level differences: Adjust exposure times and antibody concentrations accordingly

  • Context-dependent interactions: FBXL7 function may differ between cell types (as seen between glioma and pancreatic cancer)

  • Post-translational modifications: FBXL7 may undergo different modifications in different tissues

• Technical approaches:

  • Standardize protocols across experiments (fixation, antigen retrieval, antibody incubation)

  • Include internal positive controls in each experiment

  • Use absolute quantification methods (e.g., recombinant protein standards)

  • Consider multiple antibody-based methods (IHC, western blot, IF) to confirm findings

• Data interpretation:

  • Document experimental conditions thoroughly

  • Consider cell-type specific roles (e.g., FBXL7 appears to promote glioma progression but suppress pancreatic cancer progression)

  • Report inconsistencies transparently in publications

The literature highlights that FBXL7 can have different regulatory functions in different tumor cells. For example, while FBXL7 regulates Snail1 in pancreatic cancer cells, this regulation may differ in other cell types such as SW620 and MCF-7 cells .

What strategies can overcome background issues when using FBXL7 antibodies in immunohistochemistry?

Background staining can significantly impair the interpretation of FBXL7 immunohistochemistry. Based on successful IHC applications in the literature:

• Blocking optimization:

  • Use dual blocking approach (protein block followed by serum block)

  • Include blocking steps for endogenous enzymes (peroxidase, alkaline phosphatase)

  • Consider avidin/biotin blocking if using biotin-based detection systems

• Antibody optimization:

  • Titrate primary antibody carefully to find optimal dilution

  • Extend primary antibody incubation time and reduce concentration

  • Consider monoclonal antibodies if polyclonal antibodies show high background

  • Test different antibody clones targeting distinct epitopes

• Protocol modifications:

  • Increase washing duration and number of washes

  • Use detergent (0.05-0.1% Tween-20) in wash buffers

  • Optimize antigen retrieval conditions

  • Reduce secondary antibody concentration or incubation time

• Tissue-specific considerations:

  • Minimize section thickness (3-4 μm)

  • Block endogenous biotin in certain tissues (liver, kidney)

  • Adjust fixation protocols for different tissue types

These approaches have enabled researchers to successfully perform IHC analysis of FBXL7 in various tissues, including pancreatic cancer specimens where they were able to clearly differentiate positive from negative staining patterns .

How can FBXL7 antibodies be applied in in vivo metastasis models?

FBXL7 has been implicated in cancer metastasis, particularly in pancreatic cancer. To study its role in vivo using antibodies:

• Animal model selection and design:

  • Tail vein injection models: Use FBXL7-knockdown or overexpressing cancer cells (as demonstrated with shFBXL7/BxPC-3 cells)

  • Orthotopic models: Implant FBXL7-modulated cells directly into the organ of origin

  • Luciferase-labeling: Integrate luciferase expression for bioluminescent tracking of metastasis

• Tissue analysis protocols:

  • Endpoint analysis: Perform H&E staining to identify metastatic lesions in target organs

  • IHC analysis: Use FBXL7 antibodies to assess expression in primary tumors and metastases

  • Multi-marker IHC: Co-stain for FBXL7 and its targets (e.g., Snail1) or EMT markers

• Quantification approaches:

  • Record incidence and number of visible metastases

  • Measure metastatic burden via bioluminescent imaging

  • Perform quantitative image analysis of IHC staining intensity

• Controls and validation:

  • Include both positive and negative control animals

  • Validate key findings with multiple antibody clones

  • Confirm FBXL7 knockdown/overexpression persistence throughout the study

This approach has been successfully implemented to demonstrate that FBXL7 inhibition promotes pancreatic cancer metastasis in vivo. Specifically, FBXL7 knockdown in BxPC-3 cells increased the incidence of lung and liver metastasis compared to control cells, which correlated with increased Snail1 expression in the metastatic lesions .

How might FBXL7 antibodies contribute to understanding tissue-specific roles of FBXL7?

The divergent roles of FBXL7 in different cancer types present a fascinating research opportunity. FBXL7 antibodies can be instrumental in elucidating these tissue-specific functions:

• Comprehensive tissue profiling:

  • Develop tissue microarrays spanning multiple cancer types and corresponding normal tissues

  • Apply standardized FBXL7 immunostaining protocols across all samples

  • Quantify expression patterns to identify tissue-specific regulation

• Subcellular localization studies:

  • Use confocal microscopy with FBXL7 antibodies to determine localization patterns

  • Perform subcellular fractionation followed by western blotting

  • Compare localization across tissue types to identify potential functional differences

• Interaction partner identification:

  • Perform tissue-specific immunoprecipitation with FBXL7 antibodies followed by mass spectrometry

  • Compare interactome profiles between tissues where FBXL7 shows oncogenic vs. tumor-suppressive roles

  • Validate key interactions with co-IP and proximity ligation assays

• Functional domain analysis:

  • Generate domain-specific antibodies targeting different regions of FBXL7

  • Investigate whether different domains are masked or exposed in different tissues

  • Correlate domain accessibility with functional outcomes

Understanding tissue-specific roles could explain why FBXL7 is upregulated and appears oncogenic in glioma while being downregulated and displaying tumor-suppressive functions in pancreatic cancer .

Can FBXL7 antibodies be used in developing targeted therapies for cancers with aberrant FBXL7 expression?

While the search results don't directly address therapeutic applications of FBXL7 antibodies, the expression patterns and functional roles of FBXL7 suggest potential therapeutic relevance:

• Diagnostic and prognostic applications:

  • Develop standardized IHC protocols using FBXL7 antibodies for patient stratification

  • Create companion diagnostic tests to identify patients likely to respond to therapies targeting FBXL7-regulated pathways

  • Incorporate FBXL7 status into multi-marker prognostic panels

• Target validation approaches:

  • Use FBXL7 antibodies to confirm target engagement in preclinical models

  • Monitor FBXL7 pathway activity during drug treatment

  • Assess correlations between FBXL7 levels and response to targeted therapies

• Therapeutic antibody development considerations:

  • Evaluate internalization potential of FBXL7 antibodies for antibody-drug conjugate applications

  • Assess epitope accessibility in intact tumor tissues

  • Consider dual-targeting approaches combining FBXL7 with known interaction partners

• Context-dependent therapeutic strategies:

  • In glioma, where FBXL7 appears oncogenic, develop inhibitory approaches

  • In pancreatic cancer, where FBXL7 appears tumor-suppressive, explore stabilization strategies

  • Target downstream effectors based on tissue context (e.g., Snail1 in pancreatic cancer)

The tissue-specific and sometimes contradictory roles of FBXL7 highlight the importance of context-dependent therapeutic approaches. For example, enhancing FBXL7-mediated Snail1 degradation might be beneficial in pancreatic cancer , while inhibiting FBXL7 function could be appropriate in glioma .

What statistical approaches are recommended when analyzing FBXL7 antibody expression data?

Proper statistical analysis is crucial for interpreting FBXL7 expression data from antibody-based studies. Based on approaches used in the literature:

• Expression level comparisons:

  • Paired samples (e.g., tumor vs. adjacent normal): Use paired t-test or Wilcoxon signed-rank test

  • Multiple groups (e.g., different tumor grades): Apply ANOVA or Kruskal-Wallis followed by appropriate post-hoc tests

  • Binary categorization: Establish cut-off values using ROC curve analysis or median/mean splits

• Correlation with clinical features:

  • Categorical variables: Chi-square or Fisher's exact test

  • Continuous variables: Pearson or Spearman correlation coefficients

  • Survival data: Log-rank test for Kaplan-Meier curves and Cox proportional hazards regression

• Quantitative image analysis:

  • Develop standardized scoring systems for IHC (H-score, Allred score)

  • Use automated image analysis software to reduce subjective interpretation

  • Report both intensity and percent positivity when applicable

• Multi-marker analysis:

  • Assess correlations between FBXL7 and related proteins (e.g., Snail1, EMT markers)

  • Apply multivariate analysis to identify independent prognostic factors

  • Consider machine learning approaches for complex expression pattern recognition

The literature demonstrates these approaches, with studies categorizing glioma specimens into high and low FBXL7 groups based on mean expression and using Kaplan-Meier survival analysis to demonstrate significant survival differences (P < 0.001) . Similarly, Fisher's exact test was used to compare positive FBXL7 expression rates between pancreatic cancer tissues (44.0%) and adjacent normal tissues (87.5%) .

How can I resolve contradictory results between FBXL7 antibody detection methods?

When faced with contradictory results from different FBXL7 antibody detection methods, systematic troubleshooting is essential:

• Method-specific considerations:

  • Western blot: Evaluate protein extraction methods, loading controls, and transfer efficiency

  • IHC: Compare fixation protocols, antigen retrieval methods, and detection systems

  • qRT-PCR: Reconcile protein vs. mRNA level discrepancies through stability or translation efficiency analysis

• Antibody validation for each method:

  • Confirm antibody specificity in the context of each application

  • Test multiple antibodies targeting different epitopes

  • Include genetic modulation controls (knockdown/overexpression) for each method

• Biological explanations for discrepancies:

  • Post-translational modifications affecting epitope recognition

  • Protein-protein interactions masking antibody binding sites

  • Subcellular localization differences affecting extraction or accessibility

  • Isoform-specific recognition by different antibodies

• Integrated analysis approach:

  • Combine multiple detection methods to build consensus results

  • Weight evidence based on validation strength for each method

  • Report discrepancies transparently and propose biological explanations

The literature illustrates this integrated approach, with studies using both qRT-PCR and IHC to assess FBXL7 expression in pancreatic cancer. While both methods showed decreased expression in tumor tissues, the combination provided stronger evidence than either method alone .

What techniques can confirm the specificity of FBXL7 antibodies in detecting protein-protein interactions?

When investigating FBXL7 protein interactions using antibodies, confirming specificity is critical:

• Reciprocal co-immunoprecipitation:

  • Perform IP with FBXL7 antibody and blot for interaction partner

  • Perform reverse IP with antibody against interaction partner and blot for FBXL7

  • Compare results to confirm consistent interaction detection

• Genetic validation:

  • Repeat co-IP experiments in FBXL7 knockdown or knockout cells

  • Use overexpression systems with tagged FBXL7 for validation

  • Introduce mutations in key interaction domains to disrupt specific interactions

• Protein proximity assays:

  • Implement proximity ligation assays (PLA) to detect interactions in situ

  • Use FRET or BiFC approaches for live-cell interaction confirmation

  • Compare results with traditional co-IP findings

• Controls and competition assays:

  • Include IgG control immunoprecipitations

  • Perform peptide competition assays to block specific antibody binding

  • Use recombinant proteins in pull-down assays for in vitro validation

These approaches have been applied to confirm the interaction between FBXL7 and Snail1 in pancreatic cancer cells. Researchers performed co-IP assays using both anti-FBXL7 and anti-Snail1 antibodies and demonstrated their physical interaction . This was further validated by showing that FBXL7 overexpression increased Snail1 ubiquitination, confirming a functional relationship between these proteins.